Aberrant production of soluble costimulatory molecules CTLA-4, CD28, CD80 and CD86 in patients with systemic lupus erythematosus
about
RETRACTED: Functional activation of proline-rich tyrosine kinase2 (PYK2) in peripheral blood mononuclear cells from patients with systemic lupus erythematosus.Biochemical analysis of CTLA-4 immunoreactive material from human bloodA soluble form of CTLA-4 is present in paediatric patients with acute lymphoblastic leukaemia and correlates with CD1d+ expression.High levels of soluble CTLA-4 are present in anti-mitochondrial antibody positive, but not in antibody negative patients with primary biliary cirrhosis.Systemic lupus erythematosus: from genes to organ damage.CTLA-4 gene polymorphism and the risk of systemic lupus erythematosus in the Chinese population.Identification of a soluble form of B7-H1 that retains immunosuppressive activity and is associated with aggressive renal cell carcinoma.Enhancement of soluble CD28 levels in the serum of Graves' diseaseType I interferon-dependent CD86(high) marginal zone precursor B cells are potent T cell costimulators in miceRecipient CTLA-4*CT60-AA genotype is a prognostic factor for acute graft-versus-host disease in hematopoietic stem cell transplantation for thalassemia.The prognostic value of cytotoxic T-lymphocyte antigen 4 in cancers: a systematic review and meta-analysis.Preferential Induction of the T Cell Auxiliary Signaling Molecule B7-H3 on Synovial Monocytes in Rheumatoid ArthritisOverexpression and secretion of the soluble CTLA-4 splice variant in various autoimmune diseases and in cases with overlapping autoimmunity.CTLA-4 polymorphisms and haplotype correlate with survival in ALL after allogeneic stem cell transplantation from related HLA-haplotype-mismatched donorAberrant expression of costimulatory molecules in splenocytes of the mevalonate kinase-deficient mouse model of human hyper-IgD syndrome (HIDS).CD28-B7 interaction modulates short- and long-lived plasma cell function.Potentiating functional antigen-specific CD8⁺ T cell immunity by a novel PD1 isoform-based fusion DNA vaccine.Urinary CD80 excretion increases in idiopathic minimal-change diseaseImmunoregulatory soluble CTLA-4 modifies effector T-cell responses in systemic lupus erythematosus.Increased production of soluble CTLA-4 in patients with spondylarthropathies correlates with disease activityElevated expression of TIGIT on CD3+CD4+ T cells correlates with disease activity in systemic lupus erythematosus.Increased CD28 serum levels are not associated with specific clinical activity in systemic lupus erythematosus.Aberrant B-lymphocyte responses in lupus: inherent or induced and potential therapeutic targets.Targeting the alternatively spliced soluble isoform of CTLA-4: prospects for immunotherapy?Biologic therapies in systemic lupus erythematosus.The soluble CTLA-4 receptor and its role in autoimmune diseases: an updateA monoclonal antibody against CD86 and its protection in a murine lupus nephritis model of chronic graft-versus-host disease.Soluble cytotoxic T-lymphocyte antigen 4: a favorable predictor in malignant tumors after therapyA novel monoclonal antibody against human CD80 and its immune protection in a mouse lupus-like disease.Pharmacokinetic, Pharmacodynamic, and Safety Profile of a Novel Anti-CD28 Domain Antibody Antagonist in Healthy Subjects.Lack of association between sCTLA-4 levels in human plasma and common CTLA-4 polymorphisms.The soluble form of CTLA-4 from serum of patients with autoimmune diseases regulates T-cell responses.CD28 proximal promoter polymorphisms in systemic lupus erythematosus susceptibility.CTLA-4 -1722T/C polymorphism and systemic lupus erythematosus susceptibility: a meta-analysis involving ten separate studies.The -319C/+49G/CT60G haplotype of CTLA-4 gene confers susceptibility to rheumatoid arthritis in Mexican population.Expression profiles of Th17 pathway related genes in human systemic lupus erythematosus.CTLA-4 polymorphisms are associated with treatment outcomes of patients with multiple myeloma receiving bortezomib-based regimens.Curcumin modulation of the activation of PYK2 in peripheral blood mononuclear cells from patients with lupus nephritis.CCL21 and IP-10 as blood biomarkers for pulmonary involvement in systemic lupus erythematosus patients.Down-regulation of A20 mRNA expression in peripheral blood mononuclear cells from patients with systemic lupus erythematosus.
P2860
Q30887552-A1B3E7E1-C74C-4FC0-94FF-BC55B8C6AB84Q33505854-FD028DDC-239F-4379-AA91-3663ADEC3809Q34437911-C6EB3AE2-D4FC-420F-807E-23C9F12C726AQ34482952-AF66E86D-E9A1-4D04-BAD7-CE3A4B778CBDQ35156161-46F309FD-E915-49C6-804B-3CD0031D8566Q35207920-1AFBFCFC-564C-45A0-A9BC-BA1F06B523A8Q35619699-B8A02DFF-6EA0-4FC6-B776-A494D6331573Q35631893-912E9C1A-3F84-4A19-84D7-47455DFD5DCBQ35848476-08EA02E0-2681-4EAF-9A41-7611697573EFQ35859478-59DB0FDD-8C2A-4332-A04A-E54216F5350BQ36283876-FFBCF0B2-4E9E-412A-967C-D0E180ECB8F5Q36594694-77128AE8-DEFC-4057-AB4E-350DB75CB86BQ36720721-D902724C-1B7B-4E31-85DE-EA652451B966Q36842615-68AB4C1D-F229-4F4D-9A4F-8BD4AB93A283Q36845648-3E7B361A-9BC1-44FB-B4B4-29B1A9074F32Q36849492-59EDDDA2-546D-4D51-99F1-35E4224324A2Q36984486-3B126735-6BAB-471F-B625-DF7480FD1267Q37086660-35AB6D85-DBDB-4C84-B3C7-4794DC63FD08Q37150868-6F686AF3-2661-4207-AC64-168F6C009191Q37350847-88D72D1C-09AB-4B74-B09E-7328148335C2Q37673346-B756613F-1584-449F-8C44-5A6AC874B2EEQ37730555-7AF00680-C00F-4F32-A447-BDC0BCAE74B4Q38108851-D2CBA604-A215-4252-9309-0DA025DE1D67Q38271877-1E53E83F-E6C9-403F-B8FE-00479D2E5582Q38425831-1CE1EA3E-36FC-48F1-8E66-8CB928DD906FQ38497377-53BBBC4F-02C2-4C25-B713-938FE143CAB9Q38659724-24810B34-DCE8-4F8C-96B8-50497E124E28Q38819978-1D7BC0CB-01E3-4A95-961E-84BD7285849AQ39462282-6E19066D-D233-4F45-88E8-C3D5D53110FDQ40617738-18EA0D31-0979-4B14-8B7F-F3687D0C2517Q41191163-E8E05B33-85AA-4A5B-93BF-E58E412F6AAFQ41816262-2B285F61-F47C-49EB-9658-72F51196AC62Q43410554-0D981AE2-E5C0-49B5-BDBC-3AAC8E02383CQ43564970-4CD41CFA-2A88-40AE-9166-D7873BA2FCC7Q43812054-3BDB30BD-4488-42AB-8A35-4DECBD9CB00CQ44572593-FC0B7B41-D692-4A16-BB0A-D0ADF9935524Q47267543-7489BF3C-441D-4602-A2DF-8C982F73232CQ50350079-CDE52F29-2B19-434E-8458-B7B9264FD126Q51457612-17A62CBF-D496-416A-9551-3E22BA0F6146Q54296422-1329C5A7-BF5E-452F-8834-72427B0EAACB
P2860
Aberrant production of soluble costimulatory molecules CTLA-4, CD28, CD80 and CD86 in patients with systemic lupus erythematosus
description
article
@en
im Mai 2005 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в серпні 2005
@uk
name
Aberrant production of soluble ...... h systemic lupus erythematosus
@en
Aberrant production of soluble ...... h systemic lupus erythematosus
@nl
type
label
Aberrant production of soluble ...... h systemic lupus erythematosus
@en
Aberrant production of soluble ...... h systemic lupus erythematosus
@nl
prefLabel
Aberrant production of soluble ...... h systemic lupus erythematosus
@en
Aberrant production of soluble ...... h systemic lupus erythematosus
@nl
P2093
P2860
P356
P1433
P1476
Aberrant production of soluble ...... h systemic lupus erythematosus
@en
P2093
P2860
P304
P356
10.1093/RHEUMATOLOGY/KEH663
P407
P50
P577
2005-05-03T00:00:00Z